Avalo Therapeutics, Inc.
For the period ended Dec 31, 2024. Filed Mar 20, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 20, 2025
AVTX$7.16-1.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets as of December 31, 202 and
Consolidated Balance Sheets
(In thousands, except share and per share data)
| December 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $134,546 | $7,415 |
| Other receivables | 611 | 136 |
| Prepaid expenses and other current assets | 3,714 | 843 |
| Restricted cash, current portion | 19 | 1 |
| Total current assets | 138,890 | 8,395 |
| Property and equipment, net | 1,209 | 1,965 |
| Goodwill | 10,502 | 10,502 |
| Restricted cash, net of current portion | 131 | 131 |
| Total assets | $150,732 | $20,993 |
| Liabilities, mezzanine equity and stockholders’ equity | ||
| Current liabilities: | ||
| Accounts payable | $283 | $446 |
| Accrued expenses and other current liabilities | 6,317 | 4,172 |
| Derivative liability, current | 360 | — |
| Total current liabilities | 6,960 | 4,618 |
| Royalty obligation | 2,000 | 2,000 |
| Deferred tax liability, net | 270 | 155 |
| Derivative liability, non-current | 8,120 | 5,550 |
| Other long-term liabilities | 350 | 1,366 |
| Total liabilities | 17,700 | 13,689 |
| Mezzanine equity: | ||
| Series D Preferred Stock—$0.001 par value; 1 and 0 shares of Series D Preferred Stock authorized at December 31, 2024 and 2023, respectively; 1 and 0 shares of Series D Preferred Stock issued and outstanding at December 31, 2024 and 2023, respectively | — | — |
| Series E Preferred Stock—$0.001 par value; 1 and 0 shares of Series E Preferred Stock authorized at December 31, 2024 and 2023, respectively; 1 and 0 shares of Series E Preferred Stock issued and outstanding at December 31, 2024 and 2023, respectively | — | — |
| Stockholders’ equity: | ||
| Common stock—$0.001 par value; 200,000,000 shares authorized at December 31, 2024 and 2023; 10,471,934 and 801,746 shares issued and outstanding at December 31, 2024 and 2023, respectively | 10 | 1 |
| Series C Preferred Stock—$0.001 par value; 34,326 and 0 shares of Series C Preferred Stock authorized at December 31, 2024 and 2023, respectively, 24,896 and 0 shares of Series C Preferred Stock issued and outstanding at December 31, 2024 and 2023, respectively | — | — |
| Additional paid-in capital | 503,285 | 342,437 |
| Accumulated deficit | (370,263) | (335,134) |
| Total stockholders’ equity | 133,032 | 7,304 |
| Total liabilities, mezzanine equity and stockholders’ equity | $150,732 | $20,993 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.